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The present study was carried out to determine the eﬀect of berberine on glucose homeostasis and several biomarkers associated
with insulin sensitivity in male Wistar rats with intraperitoneal injection of streptozotocin (STZ)-induced diabetes. Rats with
fastingbloodglucose 16.7mmol/Lafter 2weeks ofSTZinjection were divided intotwogroups.One groupwas usedas thediabetic
control and another treated by gavage feeding with 100mg/kg/d of berberine in water containing 0.5% carboxymethyl cellulose.
A group of rats without receiving STZ was used as the normal control. After 7 weeks, berberine supplementation moderately but
signiﬁcantly lowered fasting blood glucose levels and improved oral glucose tolerance. Berberine lowered plasma free fatty acids
and C-reactive protein levels without aﬀecting plasma insulin levels. Diabetic rats treated with berberine showed signiﬁcantly
lower plasma triacylglycerol and cholesterol levels. Furthermore, berberine inhibited dipeptidyl peptidase-4 and protein tyrosine
phosphatase-1B activities. In conclusion, berberine showed a dramatic eﬀect of lowering blood cholesterol and triacylglycerols
and improved moderately glucose homeostasis in STZ-induced diabetic rats in association with multiple factors related to insulin
resistance.
1.Introduction
Berberine (BBR) is a medically important isoquinoline
alkaloid, which exists in a number of medicinal plants
and displays a broad array of pharmacological eﬀects [1].
BBR has been used in Chinese traditional medicine to
treat various infectious diseases. Recent years, this natural
compound has been increasingly studied for its beneﬁts
againstvariousmetabolicdiseasesincludingdiabetes.Several
earlystudiesdoneinstreptozotocin-(STZ-)induceddiabetic
rats demonstrated favorable eﬀects of BBR on blood glucose
control [2–4]. A recent study in rats supported the hypo-
glycemic eﬀect of BBR; however, the eﬃcacy was much less
pronounced [5]. Moreover, the mechanism through which
BBR improves diabetes is less understood.
Diabetesisamultiple-faceteddisease.Increasedoxidative
stress and chronic inﬂammation and decreased circulating
adiponectin all aﬀect insulin secretion and sensitivity [6,
7]. It is reported that BBR is protective against oxidative
stress [8–11]. However, this observation was not supported
by the results of a recent study in diabetic rats [5]. The
anti-inﬂammatory eﬀect of BBR has been demonstrated in
several in vitro studies, showing an inhibitory eﬀect on the
gene expression of TNF-α and C-reactive protein (CRP) in
macrophages and 3T3-L1 adipocytes [12, 13]. Recent in vitro
studies also showed a signiﬁcant increase in the expression of
adiponectin in 3T3-L1 adipocytes treated with BBR [13, 14].
It remains important to determine whether BBR produces
similar eﬀects on chronic inﬂammation, oxidative stress, and
circulating adiponectin levels in vivo.
Increases of circulating free fatty acids and triacylglyc-
erols aﬀect not only cardiovascular health but also insulin
secretion and function. High levels of blood triacylglycerols2 ISRN Endocrinology
are associated with elevated circulating free fatty acids [15],
which aﬀects both pancreatic beta cell function [16]a n d
peripheral insulin sensitivity [17]. It is reported that a
progressive increase of plasma free fatty acids causes a dose-
dependent inhibition of insulin-stimulated glucose uptake
and utilization in humans [18]. However, information about
how BBR aﬀects circulating free fatty acids, triacylglycerols,
and other lipids in diabetes is limited.
The importance of dipeptidyl peptidase-4 (DPP-4)
degrades glucagon-like peptide-1, which plays a critical role
in insulin secretion and signalling [19]. In general, obese
subjects present much higher risk of developing insulin
resistance and diabetes. Coincidently, a twofold increase in
DPP-4 release is observed in obese subjects compared to the
leans and reduced to the lean level after weight loss [20].
Interestingly, plasma DPP-4 activity increases in rats after
STZ injection and positively correlates with blood glucose
levels [21]. Protein tyrosine phosphatase 1B (PTP-1B) aﬀects
insulin signalling through mediating the upstream of phos-
phatidylinositol 3-kinase pathway and involves mostly the
dephosphorylation of insulin receptor and insulin receptor
substrates [22]. The importance of these two enzymes in the
regulation of glucose homeostasis and insulin signalling has
been increasingly recognized.
In the present study, we determined the hypoglycemic
and insulin-sensitizing eﬀects of BBR in rats with STZ-
induced diabetes. We have further measured blood inﬂam-
matory biomarkers, free fatty acids, insulin, adiponectin,
lipid proﬁles, liver oxidative stress biomarkers, as well as
DPP-4 and PTP-1B activities, aiming to better understand
themechanismsbywhichBBRimprovesglucosemetabolism
and homeostasis in diabetes.
2.MaterialsandMethods
2.1. Animals and Diets. Thirty-eight male Wistar rats
(Charles River Laboratories, Montr´ eal, Qu´ ebec, Canada),
150–170g, were housed individually in cages in a tempera-
ture controlled room with a 12-hour light:dark cycle. Rats
were fed a casein-cornstarch-sucrose-based semisynthetic
AIN-93G diet containing 5% fat (beef tallow:sunﬂower oil
mix (96:4, wt/wt), with free access to diet and water. After
2 weeks of adaptation, rats (n = 28) were fasted overnight
and then injected with 50mg/kg body weight of STZ (Sigma
Chemicals, Oakville, Ontario, Canada) dissolved in citrate
buﬀer (pH 4.5) to induced diabetes. Normal control animals
(NC, n = 10) were fasted overnight and injected with the
citrate buﬀer vehicle. Fasting blood glucose in STZ-treated
rats was measured 3 days later and a second injection was
applied if rats were not diabetic. Fasting blood glucose was
measured again 12 days after the ﬁrst STZ-injection. Rats
with fasting blood glucose levels over 16.7mmol/L were
divided into 2 groups (n = 10 each) and continued on the
AIN-93G diet. These two groups were matched for body
weight and blood glucose levels. One group was used as a
diabetic control (DB) and the other was orally gavaged with
berberine chloride (98% pure, Sigma Chemicals) dissolved
in 0.5% carboxymethyl cellulose at a dose of 100mg/kg/d
(BBR).TheDBandNCgroupsweregavagedwiththecontrol
vehicle of 0.5% carboxymethyl cellulose. During the 7-week
treatmentperiod,bodyweightandfoodintakewererecorded
weekly and daily, respectively.
At the end of the study, animals were fasted overnight
and anaesthetized with isoﬂurane (Pharmaceutical Partners
of Canada Inc., Richmond Hill, ON). Blood samples were
collected from the abdominal aorta into EDTA tubes and
placed on ice. After centrifugation, plasma was collected and
stored at −80◦C. Liver samples were obtained, immediately
frozen in liquid nitrogen and stored at −80◦C. The animal
use and experimental protocols were approved by the Joint
Animal Care and Research Ethics Committee of the National
Research Council Canada—Institute for Nutrisciences and
Health and the University of Prince Edward Island. The
study was conducted in accordance with the guidelines of the
Canadian Council on Animal Care.
2.2. Fasting Blood Glucose Measurements and Oral Glucose
Tolerance Testing. Fasting blood glucose was measured at
weeks 2, 3, 4, 6, and 7 in lateral tail vein blood samples using
an ACCU-Check glucose meter (Roche Diagnostics, Laval,
Quebec, Canada). Fasting blood glucose in plasma samples
was also measured in triplicate at the beginning and end of
the study with a commercial kit (Genzyme, Charlottetown,
P E ,C a n a d a ) .O r a lg l u c o s et o l e r a n c et e s t i n gw a sc o n d u c t e d
during week 6 of treatment. Following overnight fasting, rats
were orally gavaged with 2g/kg of glucose dissolved in water
(40%,wt/v).Bloodsampleswerecollectedfromtailveinat0,
15, 30, 60, and 120 minutes and measured for glucose levels
with commercial kits (Genzyme Diagnostics, Charlottetown,
PE, Canada).
2.3. Plasma Insulin and Adiponectin Measurement. Plasma
insulin and adiponectin levels were quantiﬁed in dupli-
cate using commercial ELISA kits from Crystal Chem
Inc. (Downer’s Grove, IL) according to the manufacturer’s
instructions. Standards at a series of concentrations were
run in parallel with the samples. The concentrations of
insulin and adiponectin were calculated in reference to the
corresponding standard curves.
2.4. Measurement of Liver Oxidative Stress Biomarkers. Liver
tissue was homogenized in 250μLR I P Ab u ﬀer containing
protease inhibitor and centrifuged at 1,600×g for 10 min-
utes at 4◦C. The supernatant was collected and measured
for superoxide dismutase activity and malondialdehyde
concentration according to the kit instructions (Cayman
Chemical Company, Ann Arbor, MI). For liver glutathione
and oxidized glutathione analyses, homogenized tissue was
centrifuged at 10,000×gf o r1 5m i n u t e sa t4 ◦C and the
supernatant was removed and stored on ice. Protein was
removed using MPA (metaphosphoric acid; 5g MPA in
50mL dH2O) and 4M TEAM (triethanolamine; 531μL
TEAM in 469μLd H 2O) reagents. The deproteinated super-
natant was measured for GSH concentrations following the
kit instructions. For liver GSSG, GSH in the supernatantISRN Endocrinology 3
Table 1: Eﬀect of berberine on food intake and body weight in STZ-induced diabetic rats.
Food intake (g/d)
Treatment Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7
NC 23.9 ± 1.1b 24.7 ± 1.8b 24.7 ± 1.6b 24.4 ± 1.5b 22.2 ± 2.2b 23.1 ± 1.8b 27.2 ± 2.3b
DB 45.3 ± 1.1a 41.2 ± 1.8a 40.9 ± 1.7a 39.3 ± 1.6a 38.1 ± 2.3a 41.1 ± 1.9a 44.0 ± 2.4a
BBR 43.7 ± 1.2a 43.6 ± 1.9a 42.2 ± 1.8a 40.9 ± 1.7a 36.6 ± 2.4a 43.3 ± 2.1a 43.6 ± 2.6a
Body weight (g)
Treatment Week 0 Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7
NC 277.4 ± 3.1a 316.4 ± 6.7a 356.7 ± 9.4a 385.5 ± 10.9a 417.0 ± 13.0a 439.0 ± 14.4a 457.5 ± 14.9a 483.6 ± 15.9a
DB 248.4 ± 5.7b 258.9 ± 7.5b 269.4 ± 10.5b 260.5 ± 12.1b 268.5 ± 14.5b 265.9 ± 16.1b 267.8 ± 16.7b 272.2 ± 18.7b
BBR 249.0 ± 5.3b 266.3 ± 8.0b 275.3 ± 11.2b 274.1 ± 13.0b 276.0 ± 15.5b 261.6 ± 17.2b 272.3 ± 17.8b 272.7 ± 19.0b
NC: normal control; DB: diabetic control; BBR: diabetic rats gavaged with 100mg/kg/d of berberine chloride dissolved in 0.5% carboxymethyl cellulose. The
DB and NC groups were gavaged with the control vehicle of 0.5% carboxymethyl cellulose. Data are means ± S.E.M. (n = 10 for all groups from week 0 to 5;
n = 10, 9 and 8 at weeks 5 and 6 for the NC, DB, and BBR, resp.; and n = 10, 8, and 7 at week 7 for the NC, DB, and BBR, resp.).
a,bFor each week, mean values bearing unlike superscript letters were diﬀerent, P<0.05.
was ﬁrst derivatized with 1M 2-vinylpyridine (108μL2 -
vinylpyridine in 892μL ethanol) and then the assay was
performed as per GSH.
2.5. Measurement of Plasma Inﬂammatory Cytokines. Plasma
TNF-α was quantiﬁed in duplicate using a commercial
ELISA kit (Pierce Endogen, Rockford, IL). To the anti-
TNF-α antibody-coated 96-well plate, 50μLo fs a m p l e so r
standards were added, followed by one-hour incubation at
r o o mt e m p e r a t u r e .A f t e r3w a s h e sw i t hw a s hb u ﬀer, 50μLo f
a biotinylated antibody reagent was introduced and the plate
was incubated for 1 hour at room temperature. A second
wash cycle was performed followed by addition of 100μL
of substrate TMB (3,3 ,5,5 -tetramethylbenzidine) and a
30-minutes incubation in a dark room. The reaction was
terminatedbyadding100μLofstopsolutionandabsorbance
wasreadat450nm.TNF-αconcentrationswerecalculatedin
reference to the standard curve. Plasma CRP was measured
in duplicate with a rat high-sensitivity CRP ELISA kit
(KamiyaBiomedicalCompany,Seattle,WA)followingthekit
instructions.
2.6. Plasma Lipids and Free Fatty Acid Analyses. Plasma
total cholesterol, HDL-cholesterol, and triacylglycerols were
measured in duplicate using a Pointe-180 chemistry ana-
lyzer (Pointe Scientiﬁc Inc., Canton, MI), with all reagents
purchased from the same company. Non-HDL cholesterol
was calculated by subtracting HDL-cholesterol from total
cholesterol. Plasma nonesteriﬁed fatty acids concentrations
were measured in triplicate with a commercial kit (Wako
Diagnostics, Richmond, VA).
2.7. Inhibition of DPP-4 and PTP-1B by BBR. Eﬀect of BBR
on the activity of DPP-4 and PTP-1B was measured in tripli-
cateusingthecommercialkits(EnzoLifeSciences,Plymouth
Meeting, PA) following the manufacturer’s instructions.
IC50 was obtained for each enzyme with a series dilution of
BBR in the assay buﬀer.
2.8. Statistical Analysis. Data analyses were performed
by one-way ANOVA using SAS 9.1 (SAS Institute, North
Carolina, USA). Plasma HDL-cholesterol, non-HDL-
cholesterol, and triacylglycerols were logarithmically
transformed before statistical analysis. Diﬀerences between
treatment means were determined by pairwise comparisons
using the least squares means test, where P<0.05 was
considered signiﬁcant. Results are presented as mean values
with their standard errors.
3. Results
3.1. BBR Had No Eﬀect on Food Intake and Body Weight
in Diabetic Rats. All rats in the normal control group
completed the study. Two rats in the DB and three rats
in the BBR groups either died or were euthanized due to
dehydration and hyperglycemia during weeks 5 to 7 of the
treatment. In comparison to normal controls, diabetic rats
displayed increased (P<0.0001) food intake by over 60%
during each week of the 7-week treatment period (Table 1).
BBR did not show any eﬀect on food intake. Diabetes
decreased weight gain, resulting in signiﬁcantly lower (P<
0.0001) body weights in diabetic rats compared to normal
control rats after 2 weeks of STZ-injection and over the rest
of the treatment period (Table 1). BBR treatment did not
improve weekly body weights during the entire treatment
period. Body weights in DB and BBR groups were 90% of
the normal control at the beginning and decreased to 56% of
the normal control at the end of treatment.
3.2. BBR Improved Fasting Blood Glucose Levels and Oral
Glucose Tolerance. Fasting blood glucose was measured
weeklywithaglucosemeter.Atweek3,ratsintheBBRgroup
showed signiﬁcantly lower (P<0.05) fasting blood glucose
levels than diabetic rats (25.3 ± 1.7mmol/L in BBR-treated
rats versus 29.0 ± 1.5mmol/L in diabetic controls). At the
end of the study, fasting plasma glucose levels were measured
in plasma using a commercial glucose kit. The results show
that rats treated with BBR exhibited decreased fasting blood4 ISRN Endocrinology
Table 2: Eﬀect of berberine on plasma insulin, adiponectin, and CRP levels in rats with STZ-induced diabetes.
Treatment Insulin
(pmol/L)
Adiponectin
(μg/mL) TNF-α (pg/mL) CRP (μg/mL)
NC 453.5 ± 61.8a 5.21 ± 0.4a 33.2 ± 3.4a 199.1 ± 10.0ab
DB 29.2 ± 6.9b 6.49 ± 0.36a 26.7 ± 3.4a 224.9 ± 8.6a
BBR 36.1 ± 9.0b 6.70 ± 0.61a 36.0 ± 9.8a 191.6 ± 11.3b
NC: normal control; DB: diabetic control; BBR: diabetic rats gavaged with 100mg/kg/d of berberine chloride dissolved in 0.5% carboxymethyl cellulose. The
DB and NC groups were gavaged with the control vehicle of 0.5% carboxymethyl cellulose.
CRP: C-reactive protein.
Data are means ± S.E.M. (n = 10, 8, and 7 for the NC, DB, and BBR, resp.).
a,bFor each parameter, values bearing unlike superscript letters were diﬀerent, P<0.05.
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Figure 1:OraladministrationofBBRloweredfastingbloodglucose
levels in streptozotocin-induced diabetic rats. NC: normal control;
DB: diabetic control; BBR: diabetic rats gavaged with 100mg/kg/d
of berberine chloride dissolved in 0.5% carboxymethyl cellulose.
The DB and NC groups were gavaged with the control vehicle of
0.5% carboxymethyl cellulose. Values are means ± S.E.M. (at week
0, n = 10 for all groups; at week 7, n = 10, 8, and 7 for the NC,
DB, and BBR, resp.). a, b, c Mean values with diﬀerent letters were
signiﬁcantly diﬀerent (P<0.05).
glucose levels by 20% (P<0.01) as compared with the
diabetic control (Figure 1).
Oral glucose tolerance test was performed during week
6 of the treatment. Diabetic rats showed impaired glucose
tolerance, which was improved following BBR treatment
(Figure 2). At 30 minutes post oral glucose loading, blood
glucose was signiﬁcantly lower (P<0.05) in rats treated with
BBR relative to diabetic controls.
3.3. Eﬀect of BBR on Plasma Levels of Insulin, Adiponectin,
and Inﬂammatory Biomarkers. As expected, STZ injection
dramatically decreased circulating levels of insulin. At the
beginning of treatment, diabetic rats maintained approxi-
mately 22% of blood insulin as compared to normal controls
(2.34 ± 0.41 in the normal control versus 0.52 ± 0.10 in
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Figure 2: BBR treatment improved oral glucose tolerance in
streptozotocin-induced diabetic rats. NC: normal control; DB:
diabetic control; BBR: diabetic rats gavaged with 100mg/kg/d of
berberine chloride dissolved in 0.5% carboxymethyl cellulose. The
DB and NC groups were gavaged with the control vehicle of 0.5%
carboxymethyl cellulose. Values are means ± S.E.M. (n = 10, 8, and
7 for the NC, DB, and BBR, resp.). ∗diﬀerent from the DB and BBR
groups (P<0.0001), respectively. ∗∗diﬀerent from the DB group
(P<0.05).
the diabetic group). After 7 weeks, plasma insulin levels
decreased to 8% of the normal control in the diabetic group
(P<0.0001) and were not improved in the BBR group
(10% of the normal control, Table 2). It is suggested that
BBR treatment did not recover insulin secretion function of
pancreatic β-cells.
Blood CRP concentration is an important biomarker
of chronic inﬂammation. The analysis in the current study
revealed a tendency of increase (P = 0.09) of plasma CRP
in diabetic rats (Table 2). After 7 weeks of treatment with
BBR, plasma CRP levels were reversed (P<0.05) and
became similar with the normal control. The plasma levels
of adiponectin and TNF-α were not signiﬁcantly aﬀected by
BBR (Table 2).ISRN Endocrinology 5
Table 3: Eﬀect of berberine on plasma lipids and free fatty acids in STZ-induced diabetic rats.
Treatment T-C (mmol/L) HDL-C
(mmol/L)
non-HDL-C
(mmol/L) TAG (mmol/L) FFA (mmol/L)
NC 2.12 ± 0.08c 1.51 ± 0.06a 0.61 ± 0.05c 0.99 ± 0.12b 0.58 ± 0.11b
DB 7.57 ± 1.91a 2.18 ± 0.14a 5.38 ± 1.98a 7.49 ± 2.84a 1.11 ± 0.09a
BBR 3.81 ± 0.42b 2.03 ± 0.19a 1.78 ± 0.30b 2.01 ± 0.39b 0.54 ± 0.02b
NC: normal control; DB: diabetic control; BBR: diabetic rats gavaged with 100mg/kg/d of berberine chloride dissolved in 0.5% carboxymethyl cellulose. The
DB and NC groups were gavaged with the control vehicle of 0.5% carboxymethyl cellulose.
T-C: total cholesterol; HDL-C: high-density lipoprotein cholesterol; non-HDL-C: non HDL cholesterol (very low density lipoprotein + intermediated e n s i t y
lipoprotein + low density lipoprotein cholesterol); TAG: triacylglycerols; FFA: free fatty acids.
Data are means ± S.E.M. (n = 10, 8, and 7 for the NC, DB, and BBR, resp.).
a,b,cFor each parameter, mean values bearing unlike superscript letters were diﬀerent, P<0.05.
3.4. BBR Improved Plasma Lipid and Free Fatty Acid Proﬁles.
In the present study, we found that plasma total cholesterol,
non-HDL-cholesterol, and triacylglycerols were signiﬁcantly
increased (P<0.05) in STZ-induced diabetic rats but
decreased (P<0.05) after BBR treatment (Table 3). Diabetic
rats showed almost onefold increase (P<0.05) of plasma-
free fatty acids over normal controls. After BBR treatment,
plasma-freefattyacidswerelowered(P<0.05)tothenormal
control levels.
3.5. BBR Had No Eﬀe c to nL i v e rA n t i o x i d a n tS t a t u si nS T Z -
Induced Diabetic Rats. To determine whether antioxidation
is involved in the antidiabetic properties of BBR, we
measured liver malondialdehyde, glutathione and oxidized
glutathione levels, and superoxide dismutase activity. The
analysis did not indicate any signiﬁcant changes of these
parameters in diabetic rats treated with BBR (data not
shown).
3.6. BBR Inhibited the Activity of DPP-4 and PTP-1B. To
determine whether DP-4 and PTP-1B were involved in the
beneﬁcialeﬀectsofBBRondiabetesandglucosemetabolism,
the activity of these two enzymes was measured in the
presence of diﬀerent concentrations of BBR. It was found
that BBR inhibited DPP-4 and PTP-1B activities in a dose-
dependent manner. The IC50 for DPP-4 and PTP-1B was
67μM and 205μM, respectively (Figure 3).
4. Discussion
Free fatty acids are an important causative factor of insulin
resistance and diabetes. Plasma-free fatty acids are elevated
in most obese subjects who also display a signiﬁcantly higher
rate of diabetes. Similarly, increasing blood-free fatty acids
inhibits insulin-stimulated glucose uptake into muscle [23].
This muscle insulin resistance is caused by a free fatty acid-
induced defect in insulin-stimulated glucose transport or
phosphorylation, or both. This insulin resistance is also
caused by a second defect consisting of inhibited glycogen
synthase activity [23]. The increase of free fatty acid ﬂux
stimulates hepatic gluconeogenesis while inhibiting glycogen
synthesisandthusinduceshepaticinsulinresistance[24,25].
In addition, a constantly high concentration of free fatty
acids in the bloodstream increases the accumulation of tria-
cylglycerols in both liver and muscle. Because triacylglycerols
are in a state of constant turnover, increase of triacylglycerols
results in a local accumulation of triacylglycerol metabolites
including acyl-coenzyme A, ceramides, and diacylglycerols.
These metabolites can activate a serine kinase cascade,
leading to defects in insulin signaling and glucose transport
[26]. Moreover, the modulation of transcription by free
fatty acids through their binding to peroxisome proliferator-
activated receptors impairs glucose metabolism [26]. This
consequence of events is frequently referred to as lipotoxicity
[27]. In the present study, diabetic rats showed signiﬁcantly
higherlevelsofblood-freefattyacids,whichwerereversedby
oraladministrationofBBR.Thereductionofblood-freefatty
acids was possibly achieved through increasing fat oxidation
by upregulating AMP-activated protein kinase [28]. It is
suggestedthatBBRimprovesglucosehomeostasisindiabetic
rats at least in part through lowering circulating free fatty
acids.
Apart from elevated circulating free fatty acids, chronic
inﬂammation is also strongly linked with diabetes [29, 30]
and insulin resistance [31]. Inﬂammation causes insulin
resistance via inhibiting the signaling downstream of insulin
receptor. Exposure of murine adipocytes [32]o rh a m s t e r
ovary cells [33]t oT N F - α stimulates phosphorylation of
serine residues on insulin receptor substrate-1 (IRS-1). This
phosphorylation reduces subsequent tyrosine phosphoryla-
tion of IRS-1 in response to insulin and its ability to associate
with the insulin receptor, thereby inhibiting downstream
insulin signaling [32, 34, 35]. The signiﬁcant reduction of
plasma CRP levels in diabetic rats following BBR treatment
indicates that inhibition of chronic inﬂammation is another
contributory factor, in addition to the decrease of free
fatty acids, to the observed improvement of fasting blood
glucose levels and oral glucose tolerance in BBR-treated
diabetes rats. The anti-inﬂammatory eﬀect of BBR has
been reported in several in vitro studies. A study in rat
mesangial cells showed that BBR inhibits the activation of
nuclear factor κB signaling and the protein expression of
its downstream inﬂammatory mediators [36]. BBR reduces
the gene expression of inﬂammatory biomarker CRP in
3T3-L1 adipocytes [13] and several other inﬂammatory
biomarkers such as TNF-α in macrophages [12]. On the
other hand, the anti-inﬂammatory eﬀect of BBR could be6 ISRN Endocrinology
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Figure 3: Dose response of BBR on DPP-4 (a) and PTP-1B (b) enzyme activities.
a second (or confounding) eﬀect of free fatty acid reduction
as there is a strong association between blood-free fatty acids
and chronic inﬂammation in both obese [37] and normal,
healthy subjects [15]. Free fatty acids evoke inﬂammation via
activating the proinﬂammatory nuclear factor κBp a t h w a y
[38], and BBR decreased free fatty acids.
An additional beneﬁt of BBR on diabetes derives from its
favorableeﬀectonplasmalipids. Incomparisonwithnormal
rats,diabeticratsshowedsigniﬁcantlyhigherlevelsofplasma
total cholesterol, non-HDL-cholesterol, and triacylglycerols.
After BBR treatment, plasma concentrations of these lipid
parameters were markedly lowered. In particular, BBR
decreased plasma triacylglycerol levels, consistent with the
decrease of plasma-free fatty acids. As dyslipidemia is one of
the important components of diabetes and insulin resistance
[39, 40], the reductions of blood lipids, in particular
triacylglycerols by BBR, are beneﬁcial to insulin sensitivity
and glucose utilization in the peripheral tissues [26].
DPP-4 and PTP-1B play important roles in glucose
metabolism [19, 22]. The increased activity of these two
enzymes is associated with the development of insulin
resistance and diabetes. BBR inhibited the activity of these
two enzymes in a dose-dependent manner, suggesting that
suppression of DPP-4 and PTP-1B activity was involved in
the insulin-sensitizing eﬀect of BBR.
In addition to insulin sensitivity, insulin insuﬃciency
is another important causative factor of diabetes. However,
BBR was not able to promote the pancreas to regenerate
β cells or restore β cell function in rats of STZ-induced
diabetes, in agreement with our previous study [5]. This
corroborates data observed in other animal models such as
db/db mice and diet-induced diabetic mice [41]. As reported
previously [5], BBR did not show any antioxidant eﬀect in
diabetic rats.
In conclusion, BBR supplementation lowered fasting
blood glucose and improved oral glucose tolerance in rats
with intraperitoneal injection of STZ-induced diabetes. BBR
decreased plasma chronic inﬂammation biomarker CRP,
circulating free fatty acids, and triacylglycerols levels and
inhibited DPP-4 and PTP-1B activities. The results collec-
tively demonstrate that BBR lowers considerably the blood
cholesterol and triacylglycerols while moderately improving
insulin sensitivity in association with multiple risk factors of
insulin resistance and diabetes.
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